Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

599

Shown on this page

Current sort

Live official records

Conditions: B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Interventions: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19); Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: Up to 29 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multisystem Inflammatory Syndrome in Children (MIS-C)
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: Up to 21 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 32
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
Interventions: alemtuzumab, Fludarabine, Cyclosporins, Mycophenolate mofetil, Tacrolimus; Biological · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 30 Days to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2034
U.S. locations: 11
States / cities: Chicago, Illinois • Boston, Massachusetts • Kansas City, Missouri + 6 more

Conditions: Propionic Acidemia
Interventions: mRNA-3927; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 1 Year and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 4 more

Conditions: Neuroblastoma
Interventions: Dinutuximab, NK Cells, Lenalidomide; Drug · Biological
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: Up to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Neuroblastoma
Interventions: Not listed
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 31 Days to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2099
U.S. locations: 16
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 13 more

Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Interventions: Larotrectinib, Larotrectinib surgical; Drug · Procedure
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2036
U.S. locations: 10
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: Opioid Use Disorder, Pain, Chronic
Interventions: Not listed
Lead sponsor: Sharon Levy; Other
Eligibility: 12 Years to 17 Years
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • St. Petersburg, Florida • Boston, Massachusetts + 2 more

Conditions: Eosinophilic Esophagitis Caused by Food (Disorder)
Interventions: Assay directed diet change; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 0 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions: PARP Inhibitor BGB-290, Temozolomide (TMZ); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years to 39 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Day to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 28 more

Conditions: Sickle Cell Disease
Interventions: 25 mg/day zinc, 40 mg/day zinc; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 40 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Oakland, California • Durham, North Carolina • Cincinnati, Ohio + 2 more

About this Children's Hospital of Philadelphia institution page

What this page lists: ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Children's Hospital of Philadelphia

Filter and sort this campus

Live official records

Co-administration of CART22-65s and huCART19 for B-ALL

Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Neuroblastoma Biology Study

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Adolescent Outcomes of Post-operative Opioid EXposure

EoE Food Test Pilot Study

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

About this Children's Hospital of Philadelphia institution page